Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares MSCI ACWI ETF (ACWI) vs Medpace Holdings Inc (MEDP) Price & Performance

iShares MSCI ACWI ETF
Medpace Holdings Inc

Price performance

Price movement over the last 24 hours

Key statistics

iShares MSCI ACWI ETF vs Medpace Holdings Inc — how do they compare? iShares MSCI ACWI ETF trades at $155.55, while Medpace Holdings Inc trades at $529.18 (market cap $15.60B). The key difference: iShares MSCI ACWI ETF is trading nearer its 52-week high, Medpace Holdings Inc nearer its low. Which is the better fit depends on your goals.

ACWIMEDP
52-Week High
$159.97$620.59
52-Week Low
$128.32$308.88
Market Cap
$15.60B
Sector
Technology
Enterprise Value
$15.07B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares MSCI ACWI ETF

ACWI trades at $157.97, up 1.17% with a bullish technical signal from moving averages. The ETF shows strong institutional interest and positive news flow, with a dividend scheduled for June 2026. Key support lies at $156, while resistance is at $159.

Outlook remains positive due to robust EPS growth and investor inflows into global equity ETFs. Risks include overbought technical conditions and market volatility. The stock's valuation and momentum support a constructive view for long-term investors.

Medpace Holdings Inc

Medpace (MEDP) trades at $565.09, up 1.34% with a bullish technical outlook supported by moving averages. The company demonstrates strong fundamentals with consistent earnings beats, 17.19% net margins, and robust ROE of 77.25%. Recent news highlights shifting CRO demand dynamics and upcoming Q2 2026 earnings on July 22. The stock trades near 52-week highs with technical indicators showing overbought conditions.

MEDP presents growth potential from steady revenue expansion and strong profitability, though elevated valuations (P/E 35.59) and class action lawsuits pose risks. Analyst consensus leans cautious with 63% hold ratings and $465 price target below current levels. The stock's upside depends on continued earnings outperformance and backlog quality improvement.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About iShares MSCI ACWI ETF

The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index is a free float-adjusted market capitalization index designed to measure the combined equity market performance of developed and emerging markets countries.

Read more on ACWI

About Medpace Holdings Inc

Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.

Read more on MEDP